ArticleTranslational vision science & technology2025
Smoking-Attributable Age-Related Macular Degeneration Vision Loss in China: 1990-2021 Trends and 2040 Projections.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tobacco-Attributable Age-Related Macular Degeneration Vision Impairment in Japan: A National and Prefecture-Level Analysis From 1990 to 2040.Translational vision science & technology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to analyze the spatiotemporal burden of vision loss due to age-related macular degeneration (AMD) attributable to smoking in China from 1990 to 2021, projecting to 2040. Methods: Based on the Global Burden of Diseases 2021 dataset, we quantified epidemiological metrics for AMD-related vision loss. Joinpoint regression identified trend turning points in the smoking-attributable AMD vision loss burden. The Autoregressive Integrated Moving Average model projected trajectories to 2040. Pearson correlation assessed associations between the Socio-demographic Index and burden indicators. Results: From 1990 to 2021, AMD-related vision loss cases surged approximately 200% (2021: 2,647,261 [95% uncertainty interval {UI}: 2,185,651-3,258,896]), whereas Years Lived with Disability (YLDs) rose 184% to 153,220 (95% UI: 105,756-212,586). Age-standardized YLDs rates slightly declined by 2.74% to 7.25 per 100,000. The contribution of smoking to age-standardized YLDs decreased by 13.7%, declining from 16.82% (95% UI: 10.80%-22.44%) in 1990 to 14.52% (95% UI: 9.12%-19.58%) in 2021. Smoking-attributable AMD vision loss YLDs increased 133.5% to 23,157 cases, although age-standardized rate dropped to 1.05 per 100,000. The burden was 5.8 times higher in males than females. Joinpoint regression identified 1995 as a significant turning point for trend changes. Despite declining standardized rates, smoking-attributable AMD YLD cases are projected to increase by 38.5% by 2040 in male. Conclusions: China's burden of smoking-attributable AMD vision loss exhibits male predominance and elderly clustering. Given the vast smoking population base and accelerating demographic ageing, this burden constitutes a major public health challenge. Translational Relevance: The findings provide essential data for targeted interventions. We emphasize the crucial role of smoking cessation in AMD prevention and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.